Live Intelligence
Radar
Chronological timeline of clinical trial updates, newly released atlas datasets, and critical developments in neuro-immunology.
Biogen concludes Phase 2 evaluating LRRK2 inhibitor BIIB122 in Parkinson's
Biogen and Denali Therapeutics' Phase 2 evaluation (NCT05348785) of the highly selective LRRK2 inhibitor BIIB122 in early-stage Parkinson's disease has completed its clinical cohort. LRRK2 is heavily expressed in microglia where it governs lysosomal degradation.
Denali Therapeutics completes Phase 1 trial for DNL919 ATV:TREM2
Denali has successfully concluded Phase 1 evaluation of DNL919 (NCT05450549), a TREM2 modulator engineered with their Transport Vehicle (ATV) technology to cross the blood-brain barrier for Alzheimer's disease.
Sanofi terminates Phase 2 trials for RIPK1 inhibitor SAR443820
Sanofi has ended its Phase 2 trials for the CNS-penetrant RIPK1 inhibitor SAR443820 in both Multiple Sclerosis (NCT05237284) and Amyotrophic Lateral Sclerosis (NCT05630547) due to failing to meet predefined efficacy endpoints, despite prior evidence of robust target engagement.
Alector and AbbVie discontinue Phase 2 AL002 (TREM2) trial
The INVOKE-2 Phase 2 evaluation of AL002, an activating antibody against TREM2, failed to meet its primary efficacy endpoint in early Alzheimer's disease (NCT04592874), prompting the discontinuation of the program.
Kampmann Lab releases MICA (Microglia in vitro CRISPR Atlas)
A monumental open-source functional genomic screen profiling the transcriptomic and phenotypic consequences of knocking out thousands of discrete genes in human iPSC-derived microglia.
New methodology: Targeted cellular micropharmacies delivering anti-CD33 antibodies
Researchers published a proof-of-concept utilizing genetically engineered CD4 T-cells to deliver secreted anti-CD33 scFv antibodies directly to the brain, enhancing microglial phagocytosis and bypassing classical blood-brain barrier limitations.
Vigil Neuroscience terminates IGNITE trial for VGL101 (TREM2 Agonist)
The Phase 2 evaluation of VGL101, an activating monoclonal antibody against TREM2 for ALSP patients, has been halted (NCT05677659).